全文获取类型
收费全文 | 1428篇 |
免费 | 194篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 35篇 |
妇产科学 | 12篇 |
基础医学 | 195篇 |
口腔科学 | 28篇 |
临床医学 | 58篇 |
内科学 | 231篇 |
皮肤病学 | 49篇 |
神经病学 | 72篇 |
特种医学 | 9篇 |
外科学 | 244篇 |
综合类 | 184篇 |
预防医学 | 31篇 |
眼科学 | 28篇 |
药学 | 251篇 |
中国医学 | 52篇 |
肿瘤学 | 219篇 |
出版年
2024年 | 1篇 |
2023年 | 34篇 |
2022年 | 60篇 |
2021年 | 97篇 |
2020年 | 70篇 |
2019年 | 89篇 |
2018年 | 84篇 |
2017年 | 59篇 |
2016年 | 94篇 |
2015年 | 120篇 |
2014年 | 169篇 |
2013年 | 166篇 |
2012年 | 108篇 |
2011年 | 105篇 |
2010年 | 83篇 |
2009年 | 73篇 |
2008年 | 76篇 |
2007年 | 50篇 |
2006年 | 48篇 |
2005年 | 37篇 |
2004年 | 22篇 |
2003年 | 13篇 |
2002年 | 6篇 |
2001年 | 5篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 6篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有1699条查询结果,搜索用时 46 毫秒
41.
42.
Brian Weiss Brigitte C. Widemann Pamela Wolters Eva Dombi Alexander Vinks Alan Cantor John Perentesis Elizabeth Schorry Nicole Ullrich David H. Gutmann James Tonsgard David Viskochil Bruce Korf Roger J. Packer Michael J. Fisher 《Neuro-oncology》2015,17(4):596-603
BackgroundPlexiform neurofibromas (PNs) are benign peripheral nerve sheath tumors that arise in one-third of individuals with neurofibromatosis type 1 (NF1). They may cause significant disfigurement, compression of vital structures, neurologic dysfunction, and/or pain. Currently, the only effective management strategy is surgical resection. Converging evidence has demonstrated that the NF1 tumor suppressor protein, neurofibromin, negatively regulates activity in the mammalian Target of Rapamycin pathway.MethodsWe employed a 2-strata clinical trial design. Stratum 1 included subjects with inoperable, NF1-associated progressive PN and sought to determine whether sirolimus safely and tolerably increases time to progression (TTP). Volumetric MRI analysis conducted at regular intervals was used to determine TTP relative to baseline imaging.ResultsThe estimated median TTP of subjects receiving sirolimus was 15.4 months (95% CI:14.3–23.7 mo), which was significantly longer than 11.9 months (P < .001), the median TTP of the placebo arm of a previous PN clinical trial with similar eligibility criteria.ConclusionsThis study demonstrated that sirolimus prolongs TTP by almost 4 months in patients with NF1-associated progressive PN. Although the improvement in TTP is modest, given the lack of significant or frequent toxicity and the availability of few other treatment options, the use of sirolimus to slow the growth of progressive PN could be considered in select patients. 相似文献
43.
Elena Geuna Andrea Milani Rossella Martinello Caterina Aversa Giorgio Valabrega Maurizio Scaltriti 《Expert opinion on investigational drugs》2015,24(3):421-431
Introduction: Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathway may remove this inhibition and restore sensitivity to these compounds. Buparlisib (BKM120) is a potent oral pan-class I PI3K inhibitor that is being extensively evaluated in multiple tumor types.Areas covered: This review briefly summarizes the pharmacodynamics and pharmacokinetics of buparlisib, focusing on preclinical and clinical data in BC and on ongoing randomized trials.Expert opinion: Overall, buparlisib is a safe and tolerable drug and, despite its peculiar toxicity profile, it is suitable for studies in combination with other anticancer agents in BC. Early-phase clinical trials in BC have provided evidence of antitumor activity. Several trials are being conducted in all the biological subsets of BC, including combinations with endocrine therapy, anti-HER2 agents, PARP-inhibitors and chemotherapy. While clinical results are eagerly awaited, biological material suitable for both genomic and non-genomic analyses is being collected. The authors expect an intense investigation of the potential biomarkers that explain response or resistance to buparlisib and inspire strategies to rationally explore the therapeutic potential of this drug. 相似文献
44.
哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)是衰老和衰老相关疾病的一个关键调节因子。雷帕霉素(rapamycin,RAPA)可通过抑制m TOR通路,诱导和促进细胞自噬的发生。细胞自噬是维持细胞内稳态的主要方式与途径,通过降解多余的、受损的及衰老的蛋白与细胞器,为细胞重建、再生和修复提供必需原料。早老症(hutchinson-gilford progeria syndrome,HGPS)患者细胞中伴随早老蛋白(progerin)的异常聚集;此外,诸如亨廷顿病、帕金森病、阿尔茨海默病等神经退行性疾病细胞内同样出现异常蛋白质的聚集,而这些异常蛋白的清除正依赖于细胞的自噬作用。由此可见,雷帕霉素是潜在的抗衰老、治疗早老症及衰老相关疾病的重要药物。该文主要阐述雷帕霉素促进细胞自噬方面的功能及在HGPS、神经退行性疾病方面的应用。 相似文献
45.
Long Chen Baoshan Xu Lei Liu Chunxiao Liu Yan Luo Xin Chen Mansoureh Barzegar Jun Chung Shile Huang 《Oncotarget》2015,6(9):7136-7150
mTOR is a central controller for cell growth/proliferation and survival. Recent studies have shown that mTOR also regulates cell adhesion, yet the underlying mechanism is not known. Here we found that inhibition of mTOR by rapamycin reduced the basal or type I insulin-like growth factor (IGF-1)-stimulated adhesion of cancer cells. Further research revealed that both mTORC1 and mTORC2 were involved in the regulation of cell adhesion, as silencing expression of raptor or rictor inhibited cell adhesion. Also, PP242, an mTORC1/2 kinase inhibitor, inhibited cell adhesion more potently than rapamycin (mTORC1 inhibitor). Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion. In contrast, neither genetic manipulation of Akt activity nor pharmacological inhibition of Akt affected cell adhesion. The results suggest that both mTORC1 and mTORC2 are involved in the regulation of cell adhesion; and mTORC1 regulates cell adhesion through S6K1 and 4E-BP1 pathways, but mTORC2 regulates cell adhesion via Akt-independent mechanism. 相似文献
46.
47.
48.
《Islets》2013,5(6):379-392
The aim of this study was to assess multifactorial β-cell responses to metabolic perturbations in primary rat and human islets. Treatment of dispersed rat islet cells with elevated glucose and free fatty acids (FFAs, oleate:palmitate = 1:1 v/v) resulted in increases in the size and the number of lipid droplets in β-cells in a time- and concentration-dependent manner. Glucose and FFAs synergistically stimulated the nutrient sensor mammalian target of rapamycin complex 1 (mTORC1). A potent mTORC1 inhibitor, rapamycin (25 nM), significantly reduced triglyceride accumulation in rat islets. Importantly, lipid droplets accumulated only in β-cells but not in α-cells in an mTORC1-dependent manner. Nutrient activation of mTORC1 upregulated the expression of adipose differentiation related protein (ADRP), known to stabilize lipid droplets. Rat islet size and new DNA synthesis also increased under nutrient overload. Insulin secretion into the culture medium increased steadily over a 4-day period without any significant difference between glucose (10 mM) alone and the combination of glucose (10 mM) and FFAs (240 μM). Insulin content and insulin biosynthesis, however, were significantly reduced under the combination of nutrients compared with glucose alone. Elevated nutrients also stimulated lipid droplet formation in human islets in an mTORC1-dependent manner. Unlike rat islets, however, human islets did not increase in size under nutrient overload despite a normal response to nutrients in releasing insulin. The different responses of islet cell growth under nutrient overload appear to impact insulin biosynthesis and storage differently in rat and human islets. 相似文献
49.
Pharmacological activation of AMP activated kinase (AMPK) by metformin has proven to be a beneficial therapeutic approach for the treatment of type II diabetes. Despite improved glucose regulation achieved by administration of small molecule activators of AMPK, the potential negative impact of enhanced AMPK activity on insulin secretion by the pancreatic beta cell is an important consideration. In this review, we discuss our current understanding of the role of AMPK in central functions of the pancreatic beta cell, including glucose-stimulated insulin secretion (GSIS), proliferation, and survival. In addition we discuss the controversy surrounding the role of AMPK in insulin secretion, underscoring the merits and caveats of methods used to date. 相似文献
50.